company update q1-2013

Company UpdateUnaudited YTD March 2013

April 2013

All benefits of coconut water are here

2Forward Looking StatementThis presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (Kalbe or the Company).

This presentation has been prepared solely for use in connection with the release of 31 March 2013 unaudited results of the Company. Theinformation contained in this presentation has not been independently verified. No representation, warranty or undertaking, express orimplied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or theopinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors andemployees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising fromany use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe forsecurities of the Company should not be made on the basis of the information contained in this presentation.

The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absentregistration or an exemption from registration.

This presentation and its contents are confidential unless they are or become generally available as public information in accordance withprevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in wholeor in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities ofthe Company.

This presentation, including the information and opinions contained herein, is provided as of the date of this presentation and is subject tochange without notice, including change as a result of the issuance of 31 March 2013 unaudited results of the Company .

This presentation includes "forward-looking statements". These statements contain the words "anticipate", "believe", "intend", estimate","expect" and words of similar meaning. All statements other than statements of historical facts included in this presentation, including,without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for futureoperations (including development plans, objectives relating to the Company's products and services and anticipated product launches) areforward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present andfuture business strategies and the environment in which the Company will operate in the future. These forward-looking statements speakonly as at the date of this presentation. The Company expressly disclaims any obligation or reflection of any change in the Company'sexpectations with regard thereto, or any change in events, conditions or circumstances on which any statement is based.

Market data and certain industry forecasts used in this presentation were obtained from market research, publicly available information andindustry publications which have not been independently verified, and no representation is made as to the accuracy of such information.

Table of Contents

3

Corporate Overview 4

Market Overview 7

Business Overview 11

Financial Overview 29

Corporate Actions and Outlook 2013 35

Appendix 39


SECTION 1

Corporate Overview

Prescription Pharmaceuticals

27%

Consumer Health16%

Nutritionals23%

Distribution & Logistics

35%

Established in 1966 and headquartered in Jakarta

A public company since 1991 and listed in the Indonesia Stock Exchange

The largest publicly-listed pharmaceuticals company in Southeast Asia

Sales breakdown by segment and by geographical location for YTD March 2013 is as follows:

Largest Publicly-Listed Pharmaceuticals Company in Southeast Asia

Total Sales = Rp 3,490 Bn Total Sales = Rp 3,490 Bn

Corporate Overview

Domestic, 96%

Export, 4%

5

Corporate Strategy

6

1966 1977 1985 1989 1991 1993 20051981 1994 1995 1997 2007 2010

1966:Company founded

1977:Strengthen pharmabusiness by establishing Dankos Lab

1981:Spin-off the distribution business to PT Enseval due to government regulation

1985:Expansion to consumer health through acquisition of BintangToedjoe and in pharmathrough HexpharmJaya acquisition

1989:Igar Jaya and DankosIPOs

1991:Kalbe Farma IPO

1993: Strengthening

nutritionals business by acquiring Sanghiang Perkasa and consolidating nutritional business to SanghiangPerkasa

1994: Entered

energy drink business

EPMT IPO

1995: Disposed of 50% of food business (PT Bukit Manikam Sakti) to Arnotts

1997: Disposed of Kalbes

remaining 50% ownership in PT Bukit Manikam Sakti to Arnotts

Disposed glass packaging division to Schott

Acquired Woods Peppermint brand

Acquired 80% of Saka Farma

2005:Consolidation of Kalbe Group

2006

2006:Scale through mergers and acquisitions

2007: Launch of new corporate logo

as part of transformation process

Products entered every ASEAN countries (except Laos)

Opening of the Stem Cell and Cancer Institute

Implementation of end-to-end supply chain management

Integrated information technology systems

2010: Disposed of Kageo Igar Jaya Established a joint venture

company, Asiawide Kalbe Philippines Inc.

Inaugurated Panca SradhaKalbe as our Corporate Values

Inception and Entrepreneurial

Driven Expansion19661995

Enhanced Focus and Consolidation19962005

Regionalization20062015

Kalbe has a long track record of sustainable growth

6

2011

2011: EPMT Rights Issue to

finance expansion Increased dividend

payout ratio to 50%

0

200

400

600

800

1000

1200

1400

1600

1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

(USD m

m)

0

2000

4000

6000

8000

10000

12000

14000

16000

(IDR b

n)

Sales USD Sales IDR

2012

2012: Generic production

facility comes on stream Acquired PT Hale

International Established a joint

venture company PT Kalbe Milko Indonesia


SECTION 2

Market Overview

122 139168

194221

251281

312 343

2008 2009 2010 2011 2012F 2013F 2014F 2015F 2016F

Total expenditure on health averaged 2.1%of GDP over the 11 year period 1999-2009.

Indonesias Health Spending Trends

8

BPJS Coverage - Roadmap

BPJS Health program of health coverageshall commence in Jan 2014 and intends to

cover 40%-50% of the population in the year.

It is expected that the BPJS Health will coverthe whole population in Indonesia in 2019.

4.8%

4.1%3.8%

3.5%3.3%

2.1%

0

0.2

0.4

0.6

0.8

1

1.2

0.00%

0.50%

1.00%

1.50%

2.00%

2.50%

3.00%

3.50%

4.00%

4.50%

5.00%

Malaysia Thailand Philippines India Singapore Indonesia

Healthcare Expenditure/GDP 2010

Total Healthcare Expenditure

(Rp Tn) Growth of 13.9%

Source : Business Monitor International: Pharmaceutical & Healthcare Report, Q3 2011

(Indonesia, Malaysia, Thailand, Philippines, India, Singapore)

Source : Business Monitor International: Indonesia Pharmaceuticals & Healthcare Report Q3 2012

76 mn*

30% coverage

120 mn

50% coverage

250 mn people

100% coverage

Current

20142019

* Jamkesmas members

Source : Roadmap to National Health Insurance 2012 - 2019

Pharmaceuticals Market Breakdown

9

Kalbe No. 1 in the Pharma Industry

Source: IMS QPMU 4Q 2012

Note: 2012 data adjusted for inclusion of additional companies in survey universe

Market Share

Kalbe 12%

a 6%

b 5%

c 5%

d 4%

Others 68%

Kalbe continues to be the leader in the highly fragmented

pharmaceuticals industry with over 200 players

Total Market FY 2012 Rp 50.0Tn

OTC 40%

Ethicals

60%

Branded &

Licensed

84%

Unbranded

16%

Pharma Market Breakdown

Recent Indonesian Pharmaceuticals

Regulatory

10

Ministry of Health Decree No. 092 /Menkes/SK/II/2012 issued on 23 February 2012

Replaces the previous Ministry of Health Decree No. 632 /Menkes/SK/III/2011. The Indonesian Ministry of Health has set selling price and retail price caps on 498 generics drugs for

pharmacies, hospitals and other healthcare institutions throughout Indonesia.

Ministry of Health Regulation No. 1010/MENKES/PER/XI/2008 issued on 3 November 2008 It prohibits foreign pharmaceutical companies from registering drugs in Indonesia unless they have local

production facilities.

Price Caps on Key Generic Drugs

National Healthcare Insurance System

Local Production Facilities Requirements

Ministry of Health Decree No. 094 /Menkes/SK/II/2012 issued on 23 February 2012

Replaces the previous Ministry of Health Decree No. 633 /Menkes/SK/III/2011 issued on 24 March 2011 The Indonesian Ministry of Health has set different price caps based on different regions for government

procurement in government healthcare facilities.

10

Presidential Decree No. 101 Year 2012 regarding Recipients of Health Insurance Premium Subsidy

Government will subsidize health insurance premium for poor population membersPresidential Decree No. 13 Year 2013 regarding Health Insurance

All Indonesians are required to be a member of the Health Insurance. First stage of implementation in 2014 will cover subsidy recipients, military members, civil servants, and formal

sector workers. Second stage will cover all population members by 1 January 2019.


SECTION 3

Business Overview

KALBE GROUP

13%

a8%

b6%

c6%

d4%

e4% f

3%

OTHERS57%

780 930

31 Mar 2012 (Unaudited)


SALES in Rp Bn

12

Prescription Pharmaceuticals Division

Strong Top Line Growth

No. 1 player in Indonesian Prescription PharmaMarket.

The largest medical representatives team in Indonesia with more than 2,300 personnel.

Comprehensive product offerings which covers all income groups

Gross Profit Margin (GPM) declined to 61.3% in YTD 03 2013 from 67.9% in YTD 03 2012 mostly due to

product mix and Rupiah depreciation. GPM was stable

compared to 61.8% in YTD 12 2012.

+19.2%

Branded Generics

63.4%

Unbranded Generics

10.6%

Licensed Products

26.1%

Total Sales Rp 930 Bn

Market Share (ITMA)

YTD 12 2012

Source: IMS Health Prescription Pharmaceuticals YTD 12 2012Total Market = Rp 30.1Tn

Note: 2012 data adjusted for inclusion of additional companies in survey

universe

Prescription Pharmaceuticals Division

Penetrate further in the unbranded

generics market

13

Growth Drivers

Completion of Kalbes first oncology factory in Indonesia by 2014

a26%

Kalbe16%b

13%

Others45%

Market Share Unbranded Generic (ITMA)

YTD 12 2012

Expand licensed products from

multinational companies to gain

technology transfer

Source: IMS QPMU 4Q 2012


14

Consumer Health Division

Strong Brand Equity with Leading Market Position

Market share of Kalbes brands YTD December 2012

Source : AC Nielsen jaguar method, based on volume (unit)

Note : * urban data only

** based on AC Nielsen August 2010

Therapeutic Class Kalbes Products Market Share by Volume

Antacid Promag, Waisan 73.8%*

Anti Diarrhea Neo Entrostop 44.8%**

Cough Remedies Komix, Woods, Mextril, Mixadin 33.9%

Cold Remedies Mixagrip Reg, Mixagrip FB, Procold 36.5%

Multivitamin Cerebrovit, Fatigon, Sakatonik Liver 30.8%

Children Multivitamin Cerebrofort, Sakatonik ABC 18.1%

Energy Drink ExtraJoss 23.4%

KALBE GROUP

10%

a10%

b8%

c8%

d5%

e4% f

3%

Others52%

464 557



SALES in Rp Bn

No. 1 Player in OTC market and No.2 in Energy Drink category.

GPM decreased from 54.5% in YTD 03 2012 to 53.1% in YTD 03 2013 due to change in product

mix and Rupiah depreciation. GPM amounted

to 55.2% in YTD 12 2012.


15

Strong Net Sales Performance

Energy Drink

YTD 12 2012 (Unit)

OTC

YTD 12 2012

Total Market (in volume) = 2,371Mn

Source : AC Nielsen YTD 12 2011

Total Market = Rp 19.9 Tn

Source : IMS Health ITMA OTC YTD 12 2012

+20.1%


a42.1%

Extra Joss

23.4%

b12.9%

c7.3%

d7.0%

Others7.3%


16

Innovative New Products

Hydro CocoAn isotonic drink made of real coconut water.

Tipco Fruit JuiceA healthy drink made of fruits and vegetables

Original Love Juice & PomeramaFresh bottled fruit juice made of quality fruits available in orange,

guava, apple and pomegranate flavors. Pomerama is a pioneer

and market leader in pomegranate juice in Indonesia.

Komix DTA non-drowsy cough syrup with more convenient packaging.

Bintang Toedjoe Turun Panas AnakAnalgesic product for children in convenient sachet packaging.

Bintang Toedjoe Masuk AnginTraditional herbal remedy for common cold symptoms in sachet

packaging.

NitrosConcentrated energy drink in liquid form with convenient tube

packaging.

17

Complete Range of Nutritional Products

TeenExpecting Lactating Baby Toddler Kid Tween 25+ 35+ Clinical

Catered to expecting & lactating mothers, babies, toddlers, children, tweens and adults.

Nutritionals Division


18

Growth of Indonesian Powdered Milk Market

16,159 17,550

FY 2011 FY 2012

183,157 190,398

FY 2011 FY 2012

Source : AC Nielsen, YTD 12 2012

By Value (Rp Bn)By Volume (Kg 000)

8.6%3.7%

649 796



SALES in Rp Bn


19

Strong Net Sales Performance

+22.6% Existing major products continued to gain market share.

GPM was stable at 61.5% in YTD 03 2013 from 61.6% in YTD 03 2012. GPM for YTD 12 2012 was

62.7%.

Powdered Milk Market Share YTD 12 2012

a30%

b19%

c13%

Kalbe Nutritionals

10%

d8%

e6%

f4%

g3%

h3%

i2%

Others2%

Total Market = Rp 17.5 Tn

Source : AC Nielsen, based on Value (Rp)

Kalbes Products Market Share

Diabetasol 88.1%

Milna 76.5%

Prenagen 55.6%

Morinaga Chil Mil 10.7%

Morinaga BMT 11.2%

Entrasol 8.0%

Morinaga Chil Kid 6.1%

Zee 3.7%

Morinaga Chil School 2.2%

Launching of New Products

Morinaga Soya & P-HP

Customized infant formula and growing up milk for lactose intolerance

and milk protein allergy.

20


Lovamil

A new powder milk product for expecting and lactating

mothers, targeted to the middle segment

KidZee and Zee

Powder milk for kids and tweens targeted to the

middle segment, now also available in sachet

packaging

Nutrive Benecol

Smoothie with special ingredient to lower cholesterol

Fitbar

A healthy snack bar made of oats and cereals that comes in 2 flavors,

fruits and nuts, with only 110 calories per bar, Zero Cholesterol and Zero

Trans Fat, enriched with Calcium, Vitamins A, B12 and C.

Multi Channel Customer Touch Points

21


Kalbe e-store - the 1st Online Nutrition Store in Indonesia

Nutritionals Division launched new channel of consumer order through hotline service Kalbe Home

Delivery 500-880 and online shopping through www.kalbestore.com . Kalbe Family Reward Card offers

point rewards for consumers to increase Kalbe products consumption.

Distribution & Logistics Division

22

The Most Extensive Distribution Network

Branches

66 48CitiesRDC

2

3,433

366 107

10.7%

3.1%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

12.0%

-

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

Net Sales Gross Profit Income Before Tax

1,111 1,207



SALES in Rp Bn

23

Net Sales Performance

Distribution & Logistics Division is run under PT Enseval Putera Megatrading Tbk (EPMT.JK), a publicly

listed company (91.75% owned).

Net sales represents the 3rd party product sales and distribution margin of internal product sales for consolidated

accounting purposes.

GPM increased to 27.5% in YTD 03 2013 from 26.0% in YTD 03 2012, and 27.5% in YTD 12 2012.


+8.6%

(Figures in Rp Bn)

Gross profit margin

Income before taxmargin

Distribution Business Details on Stand Alone Basis

Kalbe Group 69%

3rd Party Principals 21%

Medical Devices 2%

Raw Material Trading 7%

Major Third Party Principals by Category

Prescription

Pharmaceuticals Consumer

Medical Instrument

& Diagnostic

Fine Chemical

Raw Materials


24

315

502

673

915 870969

FY 2007 FY 2008 FY 2009 FY 2010 FY 2011 FY 2012


25

Growth Drivers

Medical Devices is an area of potential

growth, especially in the

implementation of National Healthcare

Insurance System where demand for

medical devices is projected to grow

further.

Net Sales (in Rp Bn)

CAGR

25.2%

Retail Health Services : Mitrasana Clinics

Opening of Mitrasana Clinics as aone-stop service with 4-in-1

concept, including family doctor,

pharmacy, laboratory, and

convenient store.

A 100% owned subsidiary of EPMT.

To date, Kalbe has opened 46Mitrasana clinics in Jakarta and its

Greater Area.

Medical Devices


26

Continues to expand distribution infrastructure

Collaborate with local sub-distributors to gain territorial expansion

Strengthening Distribution Network

BanjarmasinJemberSurakartaBanda Aceh

1. Expand into new territories in Indonesia

2. Upgrade existing branch facilities to improve service quality

3. Establish several Regional Distribution Centers (RDC) throughout Indonesia

4. Expand warehouse capacity

Denpasar

Marketing and Sales Infrastructure

27

The largest sales force for Pharma and Consumer Health in Indonesia

Prescription

PharmaceuticalsConsumer Health Nutritionals

Distribution &

Logistics

Infra-

structures

Indonesia

Coverage

Comments

Over 2,300 medicalrepresentatives

Over 1,000 marketing personnel

Over 2,000 sales & marketing personnel

Total of 4,000 employees

66 marketing branches throughout Indonesia

43 branches & 23 at subsidiaries

1,000 trucks 500 motorcycles

Directly cover 200,000 outlets

Products available in over 1mn outlets or

80% of total

consumer health

market

Market coverage

70% of GP market covered

90% of specialist market covered

100% of all hospitals covered

100% pharmacy coverage

Largest marketing team in Indonesia

Approximately 1,000 marketing and sales

force

Market Coverage throughout Indonesia

Most developed telemarketing team in

the nutritional sector

80% of consumer health market

100% of prescription pharma market

Largest sales force in Indonesia

Manufacturing Infrastructure

28

Operates 11 GMP facilities complying with international standards

FacilityProducts

Manufactured

Building Area

(m2)Production Lines Licenses Certification

Kalbe Farma 448 42,6849 lines of Non Beta Lactam Products

(tablet, capsule, cream, liquid oral, injection)Astellas

ISO 9001, ISO 14001,

OHSAS18001

Bintang Toedjoe 46 20,849 3 lines; effervescent, powder & liquid --ISO 9001, ISO 14001,

OHSAS18001, HACCP

Dankos Farma 189 14,9053 factories; Non Beta Lactam, Penicillin &

Cephalosporin linesDaiichi

ISO 9001, ISO 14001,

OHSAS18001

Sanghiang Perkasa 132 11,8696 lines (4 lines sachet, 1 line tin,

1 line mixed sachet)Morinaga

ISO 9001, ISO 14001, HACCP,

OHSAS18001

Saka Farma 32 1,763 Liquid, Non Beta Lactam products --ISO 9001, ISO 14001,

OHSAS18001

Hexpharm Jaya

(Cikarang)88 16,533

Solid tablet & dry syrup

(Non Beta Lactam products)-- ISO 9001

Hexpharm Jaya

(Cipanas)143 3,400 Solid, Liquid oral & semi solid -- ISO 9001

Fima 24 2,500 Large volume Parenteral Line BaxterISO 9001, ISO 14001,

OHSAS18001

Kalbe Morinaga 19 33,733 1 wet - drier line, 1 can line, 2 sachet lines Morinaga ISO 9001, ISO 22000

Orange Kalbe Ltd. - 5,000 2 lines; tablet and cream -- NAFDAC (local FDA)

Hale International 6 10,000 Semi hot-filled PET -- ISO 22000/2005 GMP, HACCP


SECTION 4

Financial Overview

Consolidated Sales

30

Strong Top Line Growth of Internal Kalbe Products

19.2%20.1% 22.6%

8.6%

16.2%

Net Sales (in Rp Bn)

780

464 649

1,111

3,005

930

557 796

1,207

3,490

Prescription Pharmaceuticals

Consumer Health Nutritionals Distribution & Logistics Consolidation



Consolidated Operating Performance

31

Stable Margin

Extensive marketing efforts to create brand awareness and support sales growth

47.9% 49.0% 48.4%

31 Dec 2012 (Audited)



26.2% 25.9% 26.5%

4.8% 5.2% 4.7%0.7% 0.7% 0.7%




Selling & Marketing

General & Administrative

Research & Development

Gross Profit Margin Operating Expenses to Net Sales Ratios

31.6% 31.8% 31.9%

16.3% 17.2% 16.5%




Operating Profit Margin

403 444



542 585



Consolidated Net Earnings

32

Sustainable Earnings Growth

Income Before Tax

(in Rp bn)

Net Income

(in Rp bn)

Income before tax margin declined from 18.0% in YTD 03 2012 to 16.8% in YTD 03 2013. As of

YTD 12 2012, income before tax margin was

stable at 16.9%

+ 8.0 %

Net income margin declined from 13.4% in YTD 03 2012 to 12.7% in YTD 03 2013. As of

YTD 12 2012, income before tax margin was

stable at 12.7%

+10.1%

43 45 44 50

48 48

142

122 110 115 107 111

27 38 35

57 41 47

158

129 120 108 114 112



31 Dec2010 (Audited)




Days of Account Receivables Days of Inventories

Days of Account Payables Net Operating Cycle

Working Capital Management

33

Improved Net Operating Cycle

End-to-end supply chain

management would be

continuously implemented

to overcome any

fluctuation in inventory

Net Operating Cycle has

been decreased by 46 days

from 158 days in 2008 to 112

days in March 2013

Consistent improvement in

working capital managementNo. of days

Solid Financial Position

34

Total Debt and Gearing Ratio Cash & Net Cash Balance

Rp 1.7 Trillion of Net Cash Position

340

25

141205 214

7.9%

0.5%

2.3%2.9% 2.9%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

8.0%

9.0%

0

50

100

150

200

250

300

350

400

FY 2009 (Audited)

FY 2010 (Audited)

FY 2011 (Audited)

FY 2012 (Audited)

YTD 03 2013 (Unaudited)

Total Debt in Rp Billion

Gearing Ratio

1,562

1,902

2,291

1,860 1,889

1,222

1,877

2,151

1,655 1,675

FY 2009 (Audited)

FY 2010 (Audited)

FY 2011 (Audited)

FY 2012 (Audited)

YTD 03 2013 (Unaudited)

Cash and Cash Equivalent in Rp Billion

Net Cash in Rp Billion


SECTION 5

Corporate Actions &

Outlook 2013

10.0 12.5 25.070.0

95.014% 17%26%

51%60%

0%

20%

40%

60%

80%

0.0

20.0

40.0

60.0

80.0

100.0

2007 2008 2009 2010 2011

Cash Dividend (Rp/share) Dividend Payout Ratio (%)

Stock Split

Corporate Actions in 2012

36

To accelerate expansion in the ready-to-drink segment, on July 6,

2012, Kalbe completed the acquisition of PT Hale International, a

health beverage manufacturing company, worth Rp 98.6 billion.

Acquisition of PT Hale International

Special Dividend Payment for Fiscal Year 2011

Kalbe has obtained the approval of the AGMS

on May 23, 2012 to pay dividend of Rp 891 bn,

or equivalent to Rp 95 per share. This reflects a

higher payout of 60% which is a special

dividend for financial year 2011.

Dividend has been paid on July 17, 2012.

Historical Dividends

Joint Venture to form PT Kalbe Milko Indonesia

Kalbe signed an agreement with PT Milko Beverage Industry to form a joint venture company, PT

Kalbe Milko Indonesia, to manufacture liquid nutritionals products with an estimated investment

of Rp 100 150 Bn.

Kalbe has conducted a 1:5 stock split from Rp. 50,- per share to Rp 10,- in October 2012 to

encourage retail investors participation.

Brands Acknowledgement

37

Strong market acceptance

Earnings Guidance 2013

Outlook 2013

38

1. Year-on-year Sales Growth 15% - 18%

2. Operating Profit Margin 16.0% -17.0%

3. Earnings per Share growth of 15% - 18%

4. Dividend payout ratio minimum 50%

Capex Rp 1 1.5 Tn for production capacity and distribution network expansion

Cancellation of Treasury Stocks - subject to shareholders approval in EGMS in

May 2013


SECTION 6Appendix

Financial InformationYTD March 31, 2013 (Unaudited)

Unaudited Financial Statement

YTD 03 2013

Consolidated Balance Sheets

40


YTD 03 2013

41



YTD 03 2013

42



YTD 03 2013

43


Consolidated Statements of Income


YTD 03 2013

44

Consolidated Statements of Income


YTD 03 2013

45

* adjusted, after stock split

31 March 2012

(Unaudited)

31 March 2013

(Unaudited) % Change


YTD 03 2013

Consolidated Statement of Cash Flows

46


YTD 03 2013

Consolidated Statement of Cash Flows

47

31 March 2012

(Unaudited) % Change

31 March 2013

(Unaudited)

THANK YOU

48

For further information:

PT Kalbe Farma Tbk.

Jalan Let.Jend. Suprapto Kav. 4

Jakarta 10510, Indonesia

Tel. : 62-21-42873888

Fax. : 62-21-42873678

Email : [email protected]

[email protected]

[email protected]

Website : www.kalbe.co.id

company update q1-2013

Documents

statementthis presentation

forwardlooking statements

securities ofthe company

company updateunaudited

statements of historical

public information

companys products

unaudited results